Abivax posts ulcerative colitis data, commits to phase 2b
Abivax has posted data from a phase 2a trial in patients with moderate-to-severe ulcerative colitis that are refractory to anti-TNF antibodies or corticosteroids. The trial linked ABX464 to improvements in mucosal healing and performance on a symptom scale, leading Abivax to commit to a phase 2b.
RedHill Biopharma: transforming treatments for gastrointestinal diseases
GI disease-focused RedHill Biopharma wants to radically improve the treatment options for these types of disorders using antibiotic combination therapy. RedHill COO Gilead Raday discusses the pipeline, starting to focus on other therapeutic areas in addition to the GI space and how the company is dealing with challenges facing the biopharma industry.
FDA Grants Rare Pediatric Disease Designation to KB105 for TGM-1 Deficient ARCI
This morning, August 23, 2018, the US Food and Drug Administration (FDA) granted a rare pediatric disease designation to Krystal Biotech’s KB105 for the treatment of patients with TGM-1-deficient autosomal recessive congenital ichthyosis (ARCI).
Catalyst gives positive hemophilia update as 2 more subjects complete study
Two additional subjects completed Catalyst Biosciences’ ongoing hemophilia Phase 2/3 trial without any bleeding or developing any anti-drug antibodies (ADAs), the company said in a statement Wednesday.
Lyme Disease Is Spreading Fast. Why Isn’t There a Vaccine?
The only vaccine was taken off the market more than 15 years ago. As reports of the disease skyrocket, researchers are working on a new one.
Samumed raises $438 million for regenerative therapies
Samumed, LLC has raised $438 million, the San Diego regenerative medicine company said Monday. The new financing round brings the total to more than $650 million since Samumed’s founding, valuing the company at $12 billion, the privately held company said.
Experimental Drug Keeps Father Of Two From Needing Kidney Transplant
“We’re studying a medicine called bardoxolone methyl. It’s made by a company called Reata,” explained Block. Hinerfeld was the first person with Alport Syndrome to try bardoxolone. Block said, after 12 weeks, Hinerfeld’s kidney function stopped declining and actually improved.
Celtaxsys cystic fibrosis drug reduces key symptom in mid-stage study
Privately held Celtaxsys Inc said on Thursday a mid-stage trial testing its experimental cystic fibrosis treatment was successful in reducing a key symptom of the genetic lung disease, but did not improve lung function.
